Compare TransMedics Group Inc (TMDX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Global X Uranium ETF — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while Global X Uranium ETF trades at $38.79 (market cap $5.48B). The key difference: Global X Uranium ETF is far larger — about 2× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Global X Uranium ETF for 62 Days on average.
| TMDX | URA | |
|---|---|---|
Market Cap | $2.74B | $5.48B |
Volume | 949,331 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $150.42 | $61.81 |
52-Week Low | $61.99 | $37.52 |
Typical Hold Time | 24 Days | 62 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
URA (Global X Uranium ETF) is trading at $38.96, down 2.43% today amid bearish technical signals. The ETF faces selling pressure with 19 sell signals versus 3 buy signals across technical indicators. Recent news highlights nuclear energy's growth potential from AI power demand and government support, though uranium ETFs have experienced volatility. The fund provides diversified exposure to uranium miners, utilities, and nuclear infrastructure companies.
The nuclear sector shows long-term potential driven by AI energy demands and government investments, but URA faces near-term technical headwinds. Key risks include commodity price volatility and concentrated holdings. Analyst sentiment remains mixed with some seeing value after recent declines while others caution about sector-specific challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
